CoChat

GluN2C/GluN2D subunit‐selective NMDA receptor potentiator CIQ reverses MK‐801‐induced impairment in prepulse inhibition and working memory in Y‐maze test in mice

Open access
Suryavanshi, P S, Ugale, R R, Yilmazer‐Hanke, D, Stairs, D J, Dravid, S M · 2014 · British Journal of Pharmacology
Cited by 96

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Despite ample evidence supporting the N‐methyl‐d‐aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia, progress in the development of effective therapeutics based on this hypothesis has been limited. Facilitation of NMDA receptor function by co‐agonists (d‐serine or glycine) only partially alleviates the symptoms in schizophrenia; other means to facilitate NMDA receptors are required. NMDA receptor sub‐types differ in their subunit composition, with varied GluN2 subunits (GluN2A‐GluN2D) imparting different physiological, biochemical and pharmacological properties. CIQ is a positive allosteric modulator that is selective for GluN2C/GluN2D‐containing NMDA receptor s (M ullasseril et al.). Experimental Approach: The effect of systemic administration of CIQ was tested on impairment in prepulse inhibition (PPI), hyperlocomotion and stereotypy induced by i.p. administration of MK‐801 and methamphetamine. The effect of CIQ was also tested on MK‐801‐induced impairment in working memory in Y‐maze spontaneous alternation test. Key Results: We found that systemic administration of CIQ (20 mg·kg−1, i.p.) in mice reversed MK‐801 (0.15 mg·kg−1, i.p.)‐induced, but not methamphetamine (3 mg·kg−1, i.p.)‐induced, deficit in PPI. MK‐801 increased the startle amplitude to pulse alone, which was not reversed by CIQ. In contrast, methamphetamine reduced the startle amplitude to pulse alone, which was reversed by CIQ. CIQ also partially attenuated MK‐801‐ and methamphetamine‐induced hyperlocomotion and stereotyped behaviours. Additionally, CIQ reversed the MK‐801‐induced working memory deficit in spontaneous alternation in a Y‐maze. Conclusion and Implications: Together, these results suggest that facilitation of GluN2C/GluN2D‐containing receptors may serve as an important therapeutic strategy for treating positive and cognitive symptoms in schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.12518

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 96

Metadata

Authors
Suryavanshi, P. S., Ugale, R. R., Yilmazer‐Hanke, D., Stairs, D. J., & Dravid, S. M.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2014-01-13
Volume
171
Issue
3
Pages
799-809
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1551425670
Cited by
96
References
18
FWCI
4.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.